GlaxoSmithKline registers 4,683 cr of net sales

The Board of Directors of the Company also recommended a Dividend at the rate of Rs. 45 per equity share of Rs. 10 each for the 15 month period ended March 31, 2014.

Commenting on the results, Zubair Ahmed, Managing Director, GlaxoSmithKline Consumer Healthcare Limited said, “We are delighted to deliver confident and industry affirming results, quarter on quarter. Our robust performance for the fifteen month period ending March 31, 2014 bears testament to our consistent focus on high science, market defining innovation, clutter breaking brand communication and integration of shopper insights in our sales initiatives. Along with growing the diversified business, we have maintained our focus on our access strategy and providing products that make our consumers do more, feel better and live longer.”

“In the coming months we will continue to make appropriate changes to our business including use of digital and social to interact and engage with our customers, create a culture of exceptional leaders and bring to our customers products based on high science and consumer insights. These will future proof the organization and help it deliver healthy growth for all stakeholders,” he added.